TRAW TRAWS PHARMA INC

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.

Conference Call and Webcast Information

  • Date: Thursday, August 14, 2025, at 8:30 AM ET
  • Participant Dial-in (U.S.): 1-877-407-0789
  • Participant Dial-in (International): 1-201-689-8562
  • Conference ID: 13754425
  • Webcast Access: 

A replay of the webcast will be available on the Investors section of the Traws website at .

About Traws Pharma, Inc.

Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. We are advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a ritonavir-independent COVID treatment, targeting the Main protease (Mpro or 3CL protease).

Traws is actively seeking development and commercialization partners for its legacy clinical oncology programs, rigosertib and narazaciclib. More details can be found on Traws’ website at /partnering.

For more information, please visit and follow us on LinkedIn.

Traws Pharma Contact:

Charles Parker

Traws Pharma, Inc.



Investor Contact:

John Fraunces

LifeSci Advisors, LLC

917-355-2395



EN
08/08/2025

Underlying

TRAWTRAWS PHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TRAWS PHARMA INC

 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLO...

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options Pre-clinical analysis of ti...

February 19, 2026 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAX...

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options Compressed tablets of tivoxavir marboxil...

January 26, 2026 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) A...

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds and faster time to sus...

January 13, 2026 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir V...

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few effective treatment options Final data analysis to be reported in January 2026 NEWTOWN, Pa., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical com...

December 17, 2025 1 EN
 PRESS RELEASE
Free
TRAW TRAWS PHARMA IN...

Traws Pharma Reports Third Quarter 2025 Results and Business Highlight...

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other assets acquired Significant cost reductions quarter over quarter NEWTOWN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health ...

November 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch